Method of treating rheumatoid arthritis using anti-IL-20 antibodies
US8728469B2 · kind B2 · utility
5Cited by
24References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 11, 2013 |
| Grant date | May 20, 2014 |
| Priority date | — |
| Expiry date | Apr 11, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.